How does A8D's PS Ratio compare to its peers?

A8D is expensive based on its Price-To-Sales Ratio (47.6x) compared to the peer average (12.7x).

How does A8D's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

A8D is expensive based on its Price-To-Sales Ratio (47.6x) compared to the European Pharmaceuticals industry average (3.1x).

What is A8D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate A8D's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of A8D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate A8D's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

AB Science (DB:A8D) - Stock Price, News & Analysis

A8D Stock Overview

A clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. More details

A8D fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Earnings have grown 15.5% per year over the past 5 years

Risk Analysis

A8D has negative shareholders equity.

Shareholders have been diluted in the past year

Does not have meaningful revenue (€1M)

Does not have a meaningful market cap (€51M)

AB Science S.A. Competitors

Cantourage Group

XTRA:HIGH

€54.9m

Apontis Pharma

XTRA:APPH

€81.3m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for AB Science
Historical stock prices
Current Share Price	€0.78
52 Week High	€3.71
52 Week Low	€0.78
Beta	1.19
11 Month Change	-11.82%
3 Month Change	-15.99%
1 Year Change	-70.73%
33 Year Change	-93.65%
5 Year Change	-84.46%
Change since IPO	-93.74%

Recent updates

Shareholder Returns

	A8D	DE Pharmaceuticals	DE Market
7D	-10.7%	-5.0%	-1.3%
1Y	-70.7%	-22.0%	7.4%

Return vs Industry: A8D underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.

Return vs Market: A8D underperformed the German Market which returned 7.1% over the past year.

Price Volatility

Is A8D's price volatile compared to industry and market?
A8D volatility
A8D Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: A8D has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: A8D's weekly volatility has decreased from 11% to 5% over the past year.

About the Company

Founded	Employees	CEO	Website
2001	40	Alain Moussy	www.ab-science.com

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia.

AB Science S.A. Fundamentals Summary

How do AB Science's earnings and revenue compare to its market cap?
A8D fundamental statistics
Market cap	€51.48m
Earnings (TTM)	-€6.04m
Revenue (TTM)	€1.08m

47.6x

P/S Ratio

-8.5x

P/E Ratio

Is A8D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A8D income statement (TTM)
Revenue	€1.08m
Cost of Revenue	€257.00k
Gross Profit	€825.00k
Other Expenses	€6.87m
Earnings	-€6.04m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.093
Gross Margin	76.25%
Net Profit Margin	-558.50%
Debt/Equity Ratio	-73.6%

How did A8D perform over the long term?

See historical performance and comparison

A8D Stock Overview

Rewards

Risk Analysis

AB Science S.A. Competitors

XTRA:HIGH

€54.9m

XTRA:APPH

€81.3m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Recent updates

AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released

New minor risk - Financial data availability

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS

AB Science Announces the Validation of Its Risk Management Plan by the French National Agency (ANSM) in Order to Restart Patient Enrollment in France

AB Science SA Announces Results from Masitinib Study AB12005 in Pancreatic Cancer Have Been Presented At the 2021 Asco Annual Meeting

AB Science SA Announces Update of Masitinib

AB Science SA Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer

AB Science Sa Announces Results from Masitinib Study AB12005 in Pancreatic Cancer, Have Been Selected for Presentation at the Upcoming Asco Annual Meeting

Full year 2020 earnings released

AB Science Sa Announces Identification of Two Tissue Biomarkers That Could Potentially Serve as Predictive Biomarkers of Response for Masitinib Treatment

AB Science Announces a New Independent Publication Confirms That Masitinib Has Anti-Vital Activity Against the SARS-CoV-2 Virus in Vitro and Is A Promising Candidate for Treating COVID-19

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €10.50001 million.

AB Science Issues A Corrective Press Release Regarding Adverse Events Information from Study AB09004 Reported on December 16, 2020

AB Science Announces That Phase 2B/3 Study Evaluating Oral in Alzheimer’S Disease Met Its Primary Endpoint

New 90-day high: €14.44

AB Science S.A. Announces That Confirmatory Phase 3 Study AB12005 with Masitinib in First Line Pancreatic Cancer with Pain Was Successful

AB Science S.A. Announces Results from masitinib Study AB07015 in Severe Asthma Have Been Selected for Presentation At an ATS Symposium Held on October 16, 2020

First half earnings released

AB Science SA Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Large Multiple Sclerosis Research Conference